May 5 (Reuters) – Fresenius Medical Care said on Tuesday its revenue fell 6% in the first quarter of 2026, weighed down by significant currency effects, mainly from the weak U.S. dollar, and recent divestitures.
The dialysis provider’s revenue was 4.61 billion euros ($5.39 billion) in the quarter, broadly in line with consensus expectations of 4.59 billion euros, according to a poll by Vara Research.
The company said its transformation programme had caused one-time costs which drove a 14% decline in reported operating income and a 22% drop in reported net income.
The strategic overhaul FMC is undergoing under CEO Helen Giza is focused on improving profitability in its core kidney care business after being spun off from former parent Fresenius.
The company confirmed its outlook for the 2026 financial year.
($1 = 0.8559 euros)
(Reporting by Patricia Weiss, writing by Bernadette Hogg, editing by Milla Nissi-Prussak)
Brought to you by www.srnnews.com